Understanding PROS logo
Understanding PROS logo
  • PIK3CA Mutations in PROS
    • About PROS
    • How PIK3CA Mutations Affect Your Body
  • PROS Conditions
    • Overview
    • Living With PROS
  • Diagnosis & Current Management
  • Talking About PROS
  • Resources & Support
Sitemap
  • Understanding PROS
  • PIK3CA Mutations in PROS
    • About PROS
    • How PIK3CA Mutations Affect Your Body
  • PROS Conditions
    • Overview
    • Living With PROS
  • Diagnosis & Current Management
  • Talking About PROS
  • Resources & Support

Find more information below

Discover more about PIK3CA mutations in PROS Learn about PIK3CA mutations and PROS conditions Understand how PROS is diagnosed Current management for PROS symptoms Explore tools to help you talk to others about PROS Access useful resources

PIK3CA-Related Overgrowth Spectrum, or PROS, conditions:

  • KTS (Klippel-Trenaunay Syndrome)
  • CLOVES syndrome (Congenital Lipomatous Overgrowth, Vascular malformations, Epidermal nevi, Scoliosis/skeletal and spinal)
  • ILM (Isolated Lymphatic Malformation)
  • MCAP or M-CM (Megalencephaly-Capillary Malformation)
  • HME (HemiMegalEncephaly)/DMEG (Dysplastic MEGalencephaly)/Focal cortical dysplasia type II
  • HHML (HemiHyperplasia-Multiple Lipomatosis)
  • FIL (Facial Infiltrating Lipomatosis)
  • FAVA (FibroAdipose Vascular Anomaly)
  • Macrodactyly
  • Muscular HH (HemiHyperplasia)
  • FAO (FibroAdipose hyperplasia or Overgrowth)
  • CLAPO syndrome (Capillary malformation of the lower lip, Lymphatic malformation of the face and neck, Asymmetry of the face and limbs, and Partial or generalized Overgrowth)
  • Epidermal nevus, benign lichenoid keratosis, or seborrheic keratosis
  • Other conditions may be identified and characterized as PROS. Talk to your doctor to find out if your condition is a PROS condition
Learn more

You are now leaving the Novartis site and moving to an external website independently operated and not managed by Novartis Pharmaceuticals Corporation. Novartis assumes no responsibility for the site. If you do not wish to leave this site, click Cancel. Or click OK to continue.

1/17 ONC-1154329

Contact Us Sitemap
Novartis logo
Novartis logo

Use of website is governed by the Terms of Use and Privacy Policy.

Copyright © 2021 Novartis AG. All rights reserved.

8/21 144238